<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1972">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364737</url>
  </required_header>
  <id_info>
    <org_study_id>20-00541</org_study_id>
    <nct_id>NCT04364737</nct_id>
  </id_info>
  <brief_title>CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients</brief_title>
  <official_title>CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at Tyler</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of
      anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms
      requiring oxygen supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 300 eligible subjects will be randomized in a 1:1 ratio to receive either
      convalescent plasma (CP) from people who have recovered from COVID-19 containing antibodies
      to SARS-CoV-2 or a placebo control, Lactated Ringer's Solution (LR) or saline solution (SS).
      Hospitalized COVID-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7
      days from the onset of illness OR within 3 days of hospitalization will be eligible to
      participate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on the WHO 11-point ordinal scale for clinical improvement at 14 days</measure>
    <time_frame>14 days post randomization</time_frame>
    <description>Uninfected 0 Uninfected; no viral RNA detected Ambulatory 1 Asymptomatic; viral RNA detected 2 Symptomatic; Independent 3 Symptomatic; assistance needed
Hospitalized:
Mild disease 4 Hospitalized; no oxygen therapy 5 Hospitalized; oxygen by mask or nasal prongs
Hospitalized:
Severe disease 6 Hospitalized; oxygen by NIV or High flow 7 Intubation &amp; Mechanical ventilation; pO2/FIO2 &gt;/= 150 or SpO2/FIO2 &gt;/=200 8 Mechanical ventilation pO2/FIO2 &lt; 150 (SpO2/FIO2 &lt;200) or vasopressors 9 Mechanical ventilation pO2/FIO2 &lt; 150 and vasopressors, dialysis or ECMO Death 10 Dead</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on the WHO 11-point ordinal scale for clinical improvement at 28 days</measure>
    <time_frame>28 days post randomization</time_frame>
    <description>Uninfected 0 Uninfected; no viral RNA detected Ambulatory 1 Asymptomatic; viral RNA detected 2 Symptomatic; Independent 3 Symptomatic; assistance needed
Hospitalized:
Mild disease 4 Hospitalized; no oxygen therapy 5 Hospitalized; oxygen by mask or nasal prongs
Hospitalized:
Severe disease 6 Hospitalized; oxygen by NIV or High flow 7 Intubation &amp; Mechanical ventilation; pO2/FIO2 &gt;/= 150 or SpO2/FIO2 &gt;/=200 8 Mechanical ventilation pO2/FIO2 &lt; 150 (SpO2/FIO2 &lt;200) or vasopressors 9 Mechanical ventilation pO2/FIO2 &lt; 150 and vasopressors, dialysis or ECMO Death 10 Dead</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison in Anti-SARS-CoV-2 antibody titers</measure>
    <time_frame>0, 1, 7, 14, 28, 90 days post randomization</time_frame>
    <description>Anti-SARS-CoV-2 titers (IgM, IgG, IgA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion positive in SARS-CoV-2 RNA</measure>
    <time_frame>0, 7, 14, 28 days post randomization</time_frame>
    <description>SARS-CoV-2 PCR in nasopharyngeal swabs</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>7, 14, 28 days post randomization</time_frame>
    <description>Rate of mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Rates of Intensive Care Unit admission</measure>
    <time_frame>7, 14, 28 days post randomization</time_frame>
    <description>Percentage of patients requiring Intensive Care Unit admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in lymphocyte</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>Lymphocyte counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in neutrophils</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>Neutrophil counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in D-dimer</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>D-dimer level</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in fibrinogen</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>Fibrinogen level</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in T lymphocyte subsets</measure>
    <time_frame>0, 7, 28 days post randomization</time_frame>
    <description>T cell subsets</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in B lymphocyte subsets</measure>
    <time_frame>0, 1, 3, 7, 14 days post randomization</time_frame>
    <description>B cell subsets</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>Coronavirus</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Convalescent donor plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated ringer's solution or sterile saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>SARS-CoV-2 convalescent plasma (1-2 units; ~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate</description>
    <arm_group_label>Convalescent donor plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.</description>
    <arm_group_label>Lactated ringer's solution or sterile saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients ≥18 years of age

          2. Hospitalized with laboratory confirmed COVID-19

          3. One or more of the following respiratory signs or symptoms: cough, chest pain,
             shortness of breath, fever, oxygen saturation ≤ 94%, abnormal CXR/CT imaging)

          4. Hospitalized for ≤ 72 hours OR within day 3 to 7 days from first signs of illness

          5. On supplemental oxygen, non-invasive ventilation or high-flow oxygen

          6. Patients may be on other randomized controlled trials of pharmaceuticals for COVID -19
             and patients who meet eligibility criteria will not be excluded on this basis.

        Exclusion Criteria

          1. Receipt of pooled immunoglobulin in past 30 days

          2. Contraindication to transfusion or history of prior reactions to transfusion blood
             products

          3. Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)

          4. Volume overload secondary to congestive heart failure or renal failure

          5. Unlikely to survive past 72 hours from screening based on the assessment of the
             investigator

          6. Unlikely to be able to assess and follow outcome due to poor functional status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mila B Ortigoza, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mila B Ortigoza, MD, PhD</last_name>
    <phone>646-634-7803</phone>
    <email>Mila.Ortigoza@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gia Cobb</last_name>
    <email>Gia.Cobb@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahalia Desruisseaux, MD</last_name>
      <email>mahalia.desruisseaux@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Mahalia Desruisseaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dushyantha Jayaweera, MD</last_name>
      <phone>305-243-0810</phone>
    </contact>
    <investigator>
      <last_name>Dushyantha Jayaweera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liise-Anne Pirofski, MD</last_name>
      <email>l.pirofski@einsteinmed.org</email>
    </contact>
    <investigator>
      <last_name>Liise-Anne Pirofski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mila Ortigoza, MD, PhD</last_name>
      <email>Mila.Ortigoza@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Mila Ortigoza, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Ostrosky, MD</last_name>
      <email>Luis.Ostrosky-Zeichner@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Ostrosky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Philley, MD</last_name>
      <email>Julie.Philley@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Philley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

